{"log_id": 4951576637555746373, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 0.003858, "average": 0.972882, "min": 0.675063}, "location": {"width": 1160, "top": 312, "height": 47, "left": 244}, "words": "等、HMG-CoA还原酶抑制剂辛伐他汀和洛伐他汀以及咪达唑仑等药物,慎与经CYP2C9代谢"}, {"probability": {"variance": 0.003853, "average": 0.974962, "min": 0.740183}, "location": {"width": 913, "top": 354, "height": 47, "left": 244}, "words": "的药物同时应用,如华法林、苯妥英、某些磺酰脲类降糖药如格列本脲等"}, {"probability": {"variance": 0.000109, "average": 0.995036, "min": 0.960077}, "location": {"width": 376, "top": 399, "height": 38, "left": 301}, "words": "引起心脏QT间期延长的药物"}, {"probability": {"variance": 0.000113, "average": 0.995581, "min": 0.940054}, "location": {"width": 1103, "top": 440, "height": 47, "left": 301}, "words": "由于同类药物在临床上有延长QT间期的毒副作用,本品临床研究观察到QT间期延长的"}, {"probability": {"variance": 0.011727, "average": 0.955086, "min": 0.488007}, "location": {"width": 1160, "top": 484, "height": 47, "left": 244}, "words": "发生率为0.57%(1/176)。因此在服用期间应慎用延长QT间期的药物,并在用药期间严密监"}, {"probability": {"variance": 5e-06, "average": 0.99661, "min": 0.994272}, "location": {"width": 116, "top": 530, "height": 31, "left": 244}, "words": "测心电图"}, {"probability": {"variance": 1.6e-05, "average": 0.996318, "min": 0.988301}, "location": {"width": 379, "top": 568, "height": 43, "left": 287}, "words": "其他对肝肾功能有影响的药物"}, {"probability": {"variance": 0.000117, "average": 0.993972, "min": 0.955511}, "location": {"width": 1057, "top": 612, "height": 47, "left": 287}, "words": "服用本品期间应慎用其他对肝肾功能有影响的药物,并在用药期间严密监测肝肾功能"}, {"probability": {"variance": 6e-06, "average": 0.998269, "min": 0.993049}, "location": {"width": 157, "top": 655, "height": 36, "left": 253}, "words": "【药物过量】"}, {"probability": {"variance": 0.000283, "average": 0.991234, "min": 0.924949}, "location": {"width": 1101, "top": 699, "height": 45, "left": 299}, "words": "目前尚不清楚过量服用阿帕替尼可能产生的症状,也没有针对服用过量阿帕替尼的特异疗"}, {"probability": {"variance": 0.010843, "average": 0.955332, "min": 0.542647}, "location": {"width": 1162, "top": 740, "height": 50, "left": 239}, "words": "法。在本品I期临床研究中,部分患者服用阿帕替尼的最高剂量达100mg/天,在此剂量下观"}, {"probability": {"variance": 2.3e-05, "average": 0.997681, "min": 0.980188}, "location": {"width": 710, "top": 785, "height": 38, "left": 239}, "words": "察到的不良反应主要为34级血压升高和3级手足综合征"}, {"probability": {"variance": 0.007865, "average": 0.974126, "min": 0.491347}, "location": {"width": 968, "top": 827, "height": 45, "left": 299}, "words": "如怀疑服用药物过量,则应停药并对患者进行密切观察和给予相应的支持治疗"}, {"probability": {"variance": 0.000158, "average": 0.990413, "min": 0.972006}, "location": {"width": 157, "top": 872, "height": 36, "left": 244}, "words": "【临床研究】"}, {"probability": {"variance": 0.006939, "average": 0.978997, "min": 0.5336}, "location": {"width": 858, "top": 916, "height": 43, "left": 299}, "words": "在两项随机对照研究中评价了本品单药用于晚期胃癌的疗效和安全性"}, {"probability": {"variance": 0.013624, "average": 0.965802, "min": 0.389737}, "location": {"width": 1101, "top": 959, "height": 38, "left": 299}, "words": "一项多中心、随机、双、安慰剂平行对照的Ⅲ期临床研究对阿帕替尼治疗晚期胃癌的有"}, {"probability": {"variance": 0.003508, "average": 0.984866, "min": 0.704168}, "location": {"width": 1146, "top": 998, "height": 45, "left": 239}, "words": "效性和安全性进行了评价。研究入组了267例既往接受过二线治疗后失败(治疗失败的定义"}, {"probability": {"variance": 0.015382, "average": 0.959727, "min": 0.469112}, "location": {"width": 1158, "top": 1041, "height": 41, "left": 242}, "words": "毒副作用不可耐受、治疗过程中疾病进展或治疗结束后复发)的晚期胃癌患者,包括胃食管"}, {"probability": {"variance": 0.000719, "average": 0.984849, "min": 0.877769}, "location": {"width": 1160, "top": 1082, "height": 43, "left": 239}, "words": "结合部腺癌患者。接受阿帕替尼治疗患者中位年龄58岁,75%为男性;27%患者ECOG评分"}, {"probability": {"variance": 0.007359, "average": 0.971485, "min": 0.475534}, "location": {"width": 1160, "top": 1126, "height": 36, "left": 239}, "words": "为0,73%患者ECOG评分为1;约60%进行过根治术治疗,约22%进行了胃全切手术,35%"}, {"probability": {"variance": 0.005091, "average": 0.979821, "min": 0.539085}, "location": {"width": 1158, "top": 1167, "height": 41, "left": 239}, "words": "进行了胃大切手术;68%原发灶为胃癌,22%为胃食管结合部腺癌;21%患者转移灶累积器官"}, {"probability": {"variance": 0.001612, "average": 0.980095, "min": 0.813321}, "location": {"width": 1160, "top": 1206, "height": 45, "left": 239}, "words": "数超过2个,56%患者存在肝转移,92%患者临床分期为Ⅳ期;66%患者往接受过至少2"}, {"probability": {"variance": 0.011288, "average": 0.96532, "min": 0.358641}, "location": {"width": 1160, "top": 1249, "height": 43, "left": 239}, "words": "种系统化疗,一化疗基础用药包括氟尿嘧啶类、铂类、紫杉醇类、阿霉素类化疗主要"}, {"probability": {"variance": 0.01055, "average": 0.961973, "min": 0.427009}, "location": {"width": 1160, "top": 1290, "height": 43, "left": 239}, "words": "以伊立替康为基础治疗的方案。试验组与安慰剂组受试者基线特征和人口学数据均衡比。患"}, {"probability": {"variance": 0.015505, "average": 0.951256, "min": 0.449084}, "location": {"width": 1162, "top": 1334, "height": 36, "left": 239}, "words": "者按2:1随机接受阿帕替尼片850mg每日1次(n=176)或安慰剂每日一次=91)28天"}, {"probability": {"variance": 0.001154, "average": 0.989243, "min": 0.794892}, "location": {"width": 1158, "top": 1375, "height": 38, "left": 239}, "words": "为一个周期。试验组患者平均接受治疗周期数为2.9,72%的受试者接受了2个周期或以上的"}, {"probability": {"variance": 0, "average": 0.999938, "min": 0.999932}, "location": {"width": 59, "top": 1418, "height": 31, "left": 237}, "words": "治疗"}, {"probability": {"variance": 0.011978, "average": 0.949179, "min": 0.556084}, "location": {"width": 1105, "top": 1459, "height": 38, "left": 294}, "words": "研究主要疗效评价指标为总生存期(OS),次要疗效指标包括无进展生存期(PFS)、疾"}, {"probability": {"variance": 0.00436, "average": 0.971755, "min": 0.677284}, "location": {"width": 1158, "top": 1500, "height": 38, "left": 239}, "words": "疾病控制率(DCR)和客观缓解率(ORR)。试验组中位总生存期较安慰剂组延长,降低死亡"}, {"probability": {"variance": 0.000178, "average": 0.992038, "min": 0.940707}, "location": {"width": 1158, "top": 1544, "height": 36, "left": 239}, "words": "风险约30%次要终点PFS、DCR亦高于安慰剂组,总体上未引起晚期胃癌特异症状或健康"}, {"probability": {"variance": 0.000615, "average": 0.991133, "min": 0.862699}, "location": {"width": 854, "top": 1585, "height": 36, "left": 239}, "words": "相关生活质量的恶化。表3列出了主要疗效结果,图1为生存曲线图"}, {"probability": {"variance": 0.014479, "average": 0.95377, "min": 0.490907}, "location": {"width": 744, "top": 1633, "height": 34, "left": 434}, "words": "表3,阿帕替尼治疗胃癌的Ⅲ期临床研究的主要有效性结果(FAS集"}, {"probability": {"variance": 0.00047, "average": 0.978237, "min": 0.95655}, "location": {"width": 54, "top": 1683, "height": 29, "left": 523}, "words": "指标"}, {"probability": {"variance": 0.022278, "average": 0.916279, "min": 0.498635}, "location": {"width": 162, "top": 1681, "height": 34, "left": 804}, "words": "试验组(=176)"}, {"probability": {"variance": 0.004279, "average": 0.948737, "min": 0.819098}, "location": {"width": 180, "top": 1683, "height": 31, "left": 1066}, "words": "安慰剂组(N-91)"}, {"probability": {"variance": 0.007454, "average": 0.935501, "min": 0.785808}, "location": {"width": 166, "top": 1731, "height": 29, "left": 358}, "words": "总生存期(os"}, {"probability": {"variance": 0.044479, "average": 0.851705, "min": 0.450288}, "location": {"width": 226, "top": 1779, "height": 29, "left": 395}, "words": "中位数(mOs,月"}, {"probability": {"variance": 0, "average": 0.99543, "min": 0.99543}, "location": {"width": 20, "top": 1784, "height": 22, "left": 1155}, "words": "7"}, {"probability": {"variance": 0.036145, "average": 0.866748, "min": 0.482412}, "location": {"width": 123, "top": 1827, "height": 31, "left": 402}, "words": "R(95%c)"}, {"probability": {"variance": 0.003211, "average": 0.971716, "min": 0.756892}, "location": {"width": 207, "top": 1832, "height": 27, "left": 909}, "words": "0.709(0.537,0.937"}, {"probability": {"variance": 0.006101, "average": 0.933704, "min": 0.727516}, "location": {"width": 228, "top": 1875, "height": 31, "left": 367}, "words": "无进展生存期(PFS"}], "language": -1}